Roche has retained its status as the neurology drugmaker that patient groups hold in the highest esteem, once again completing a clean sweep of PatientView’s corporate reputation rankings.
PatientView surveyed (PDF) 352 neurology patient groups about individual drugmakers and pharma in general. Respondents named Roche, including its Genentech and Chugai units, as the best company that they worked with and that they were familiar with. Claiming the top spots on those two rankings meant Roche also placed first on lists of Big Pharma companies that groups worked with or were familiar with.
The results extend Roche’s dominance of the neurology rankings. After placing (PDF) fourth and fifth on the leaderboards in the 2018 survey, Roche climbed to the top spots on the working with and familiar with rankings in the 2019 poll. Roche has placed first on both lists ever since.
Neurology has become increasingly important to Roche over its years at the top of the rankings. In the first half of 2026, Roche reported (PDF) almost 5 billion Swiss francs ($6.2 billion) in neurology sales, making the therapeutic area responsible for 21% of revenues. Neuroscience sales hit (PDF) 2.4 billion Swiss francs—10% of the total—in the first half of 2020.
Roche’s increasing reliance on neurology sales reflects the continued growth of the multiple sclerosis treatment Ocrevus, which was already a blockbuster in 2020, and the launches of Evrysdi, Enspryng and Elevidys. Studies of trontinemab in Alzheimer’s disease drove increases in Roche’s spending in neurology in the first half of 2026. Roche has started three phase 3 trontinemab trials over the past 12 months.
The investment could support Roche’s efforts to stay ahead of the pack of companies that have jostled for second place since its reign began. UCB came second on the familiar with and working with lists in the latest survey, followed by Novartis and Boehringer Ingelheim, respectively. Lundbeck, which ranked second on both lists last year, and PTC Therapeutics slipped off the leaderboards.
PatientView provided a high-level view of patient groups’ shifting views of pharma in general. Over the past five years, the groups’ views of the industry’s transparency in the funding of external stakeholders, efforts to ensure patient safety and nine other areas improved. However, perceptions of the industry’s innovation fell over the same period.